Medication info
Empamax M Sustained Release Tablet 25/1000 mg (Empagliflozin, Metformin)

Empamax M Sustained Release Tablet 25/1000 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin L-Proline›31.38mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Dark pink oval sustained-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501899 · Approved 2025.07.24 · Insurance code 643310010

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. This medicine should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. Patients taking this medicine as 10/1000 mg or 25/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 12.5/1000 mg or 12.5/750 mg extended-release tablets should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, this medicine should be swallowed whole without splitting, crushing, grinding, or chewing. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose of this medicine is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from concomitant therapy with empagliflozin and metformin to this medicine should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted as appropriate. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dosage adjustment according to renal function is necessary, assessment of renal function is recommended before starting this medicine and periodically thereafter. No dosage adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and do not have other conditions that may increase the risk of lactic acidosis, this medicine may be used with metformin hydrochloride dose adjustment as follows. Because the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this medicine should be discontinued immediately. In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Poor blood sugar control in adult patients with type 2 diabetes
  • cardiovascular disease
View approved original text

This medication helps improve blood sugar control in adult patients with type 2 diabetes who have not achieved adequate control with diet and exercise. Caution should be taken in patients at risk for cardiovascular disease, and detailed information regarding cardiovascular events can be referenced in clinical trial information for professionals. This medication is used to enhance blood sugar control in adult patients with type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. This medicine should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. Patients taking this medicine as 10/1000 mg or 25/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 12.5/1000 mg or 12.5/750 mg extended-release tablets should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, this medicine should be swallowed whole without splitting, crushing, grinding, or chewing. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose of this medicine is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from concomitant therapy with empagliflozin and metformin to this medicine should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted as appropriate. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. Because dosage adjustment according to renal function is necessary, assessment of renal function is recommended before starting this medicine and periodically thereafter. No dosage adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2] who tolerate treatment well and do not have other conditions that may increase the risk of lactic acidosis, this medicine may be used with metformin hydrochloride dose adjustment as follows. Because the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this medicine should be discontinued immediately. In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.

Precautions

This medication is used to treat diabetes and has a blood sugar-lowering effect. However, it can rarely cause serious side effects such as lactic acidosis, so caution is required regarding this symptom. Lactic acidosis can manifest as muscle pain, weakness, breathing difficulties, and abdominal pain, and if these symptoms occur, medical consultation should be sought immediately. Additionally, this medication may increase the risk of hypoglycemia when taken with insulin or sulfonylureas, so dosage adjustments may be needed. Patients with impaired kidney function or those with acute infections, dehydration, heart failure, or acute myocardial infarction should not use this medication. In particular, this medication should be temporarily discontinued before and after tests involving iodinated contrast agents, and therapy should be resumed only after kidney function has been confirmed to be normal. It is advisable for pregnant women or those who may become pregnant and patients with liver function disorders to avoid using this medication. During treatment with this medication, urinary or genital infections may occur, and prompt treatment is necessary if symptoms of infection arise. Caution should be taken for elderly patients or those at risk for dehydration regarding fluid loss. Additionally, vitamin B12 levels may decrease, so regular testing is recommended if necessary. Alcohol consumption may increase the risk of lactic acidosis, so drinking alcohol should be avoided. In cases of surgery or severe illness, this medication should be temporarily discontinued and resumed only after the condition stabilizes. This medication should be swallowed whole and not crushed or chewed, although the tablet coating may pass in stool, which is normal. Serious side effects may occur in cases of overdose, so prescribed dosages should be adhered to, and any unusual symptoms should prompt immediate medical attention. Lastly, it should be stored out of reach of children and kept in its original container for safety.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • decreased fluid volume
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
Show 152 more
  • constipation
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • decreased and deficiency of vitamin B12
  • ketoacidosis
  • perineal necrosis
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colonic hemorrhage
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • acute pyelonephritis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • headache
  • dizziness
  • positional vertigo
  • asthenia
  • chest discomfort
  • chest pain
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weight loss
  • urinary stones
  • cervical inflammation
  • hyperglycemia
  • hyponatremia
  • vulvar pruritus
  • insomnia
  • anxiety
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • otalgia
  • postural vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodules
  • diabetic foot
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrosis
  • ocular discomfort
  • ocular congestion
  • pathologic myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • traction retinal detachment
  • eyelid edema
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • retained sputum
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery occlusive disease
  • benign neoplasm of the ampulla of Vater
  • benign ovarian tumor
  • bladder cancer
  • cholesteatoma
  • stomach cancer
  • leiomyoma
  • pancreatic carcinoma
  • rectal cancer
  • thyroid cancer
  • uterine leiomyoma
  • anxiety
  • depression
  • sleep disorders

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. It is advisable to maintain the storage temperature between 1 to 30 degrees Celsius to preserve the medication's effectiveness and safety.

Appearance and packaging

Appearance

Dark pink oval sustained-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.